Aurigene Announces Completion of Purchase of Discovery Research Facility in Hyderabad
Aurigene has completed the purchase of an additional site in Hyderabad with a fully integrated infrastructure and complement of high-quality and experienced scientific staff for Drug Discovery. This facility, along with all the physical infrastructure and scientific and non-scientific team, is now a part of Aurigene. Aurigene-Hyderabad is the erstwhile Drug Discovery site of Dr. Reddy’s Laboratories Ltd. Aurigeneâ€™s business model, as an independent subsidiary of Dr. Reddy’s, and externally focused on Drug Discovery collaborations and Services remains the same; with the addition of this site, Aurigene capacity and capabilities will increase significantly. Aurigene-Hyderabad (as the new site will be know can take up IND-enabling GLP studies including Toxicology and PK in higher, non-rodent species. This will therefore expand Aurigeneâ€™s ability to add considerably more value to its collaborations. In addition, Aurigene-Hyderabad has significant Pharmacology capabilities in Pain, Inflammation and Anti-bacterials.
Established in Bangalore, India, in 2002, Aurigene Discovery Technologies Ltd. is a drug discovery biotech with a proven track record of successful partnerships with big and medium-sized pharma and biotech companies globally. Aurigene has 10 drug discovery collaborations and a pipeline of 16 discovery programs at various stages, from Hit Generation to late-stage Pre-Clinical Optimization, and has filed 16 patents across 6 programs. With proprietary Structural Biology and Fragment-based Drug Design technology platforms, and experienced scientific leadership, Aurigene is a fully integrated Drug Discovery company focused on Oncology, Inflammation and Metabolic Disorders.